Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02563847
Other study ID # EKBB 2014/072
Secondary ID
Status Completed
Phase N/A
First received May 26, 2015
Last updated September 28, 2015
Start date May 2014

Study information

Verified date September 2015
Source University Hospital, Basel, Switzerland
Contact n/a
Is FDA regulated No
Health authority Switzerland: Ethikkommission
Study type Interventional

Clinical Trial Summary

With this study the investigators investigate the effects of amino acids (tryptophan in two different concentrations, leucin) and sugar alcohols (xylitol, erythritol) on satiety mechanisms.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date
Est. primary completion date March 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria:

- Healthy normal weight subjects with a body-mass index of 19.0-24.9

- Healthy obese subjects with a body-mass index of > 30

- Normal eating habits (no diets; no dietary changes; no special dietary habits, such as vegetarian/vegan)

- Age 18-40 years

- Stable body weight for at least three months

Exclusion Criteria:

- Smoking

- Substance abuse

- Regular intake of medications (except for oral contraceptives)

- Medical or psychiatric illness

- History of gastrointestinal disorders

- Food allergies

- Pregnancy, breast feeding

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
0.52 g L-Tryptophan

1.56 g L-Tryptophan

1.56 g L-Leucine

50 g Xylitol

75 g Erythritol

75 g Glucose

300 mL tap water

Other:
50 mg 13C-sodium acetate


Locations

Country Name City State
Switzerland University Hospital Basel, Phase 1 Research Unit Basel

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Basel, Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Effect of different aminoacids and sugar alcohols on secretion of satiation hormones Plasma concentrations of glucose changes from baseline to three hours after treatment No
Primary Effect of different aminoacids and sugar alcohols on secretion of satiation hormones Plasma concentrations of insulin are measured changes from baseline to three hours after treatment No
Primary Effect of different aminoacids and sugar alcohols on secretion of satiation hormones Plasma concentrations of glucagon are measured changes from baseline to three hours after treatment No
Primary Effect of different aminoacids and sugar alcohols on secretion of satiation hormones Plasma concentrations of glucagon-like Peptide (GLP-1) are measured changes from baseline to three hours after treatment No
Primary Effect of different aminoacids and sugar alcohols on secretion of satiation hormones Plasma concentrations of PYY are measured changes from baseline to three hours after treatment No
Primary Effect of different aminoacids and sugar alcohols on secretion of satiation hormones Plasma concentrations of cholecystokinin are measured changes from baseline to three hours after treatment No
Secondary Effect of different aminoacids and sugar alcohols on gastric emptying measured by C13 breath test changes from baseline to four hours after treatment No
See also
  Status Clinical Trial Phase
Recruiting NCT05544266 - Rare and Atypical Diabetes Network
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A
Active, not recruiting NCT05505994 - The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin Phase 3
Completed NCT03675360 - Low-Carbohydrate Dietary Pattern on Glycemic Outcomes Trial N/A
Recruiting NCT03682640 - Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes Phase 2
Terminated NCT00935766 - Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries Phase 3
Terminated NCT00174187 - Treatment With Recombinant Human Growth Hormone (GH) in Children With Short Stature Secondary to a Long Term Corticoid Therapy Phase 3
Completed NCT03717298 - Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma Phase 2
Active, not recruiting NCT05014204 - Safety and Feasibility of Novel Therapy for Duodenal Mucosal Regeneration for Type II Diabetes N/A
Completed NCT03562897 - Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer Phase 2
Completed NCT01727973 - Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy Phase 1/Phase 2
Recruiting NCT06112340 - A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) Phase 2/Phase 3
Active, not recruiting NCT05445284 - Group Education Trial to Improve Transition for Parents of Adolescents With T1D N/A
Terminated NCT04371978 - Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19 Phase 3
Completed NCT03725813 - Study Evaluating the Effect of Person-centred Care for Patients Admitted for Inpatient Care at an Internal Medicine Unit N/A
Recruiting NCT04556071 - Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer Phase 2
Terminated NCT03335254 - A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males Phase 1/Phase 2
Completed NCT04488432 - Endocrine, Bone And Metabolic Disorders In Adults After Allogeneic Stem-cell Transplant
Recruiting NCT05084079 - Different Initial Insulin Dose Regimens on Time to Achieve Glycemic Targets and Treatment Safety in SIIT Phase 4
Completed NCT03305016 - A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency Phase 3